Faron Closes HIBISCUS Trial
Faron Pharmaceuticals Ltd. (“Faron” or “Company”) Faron Closes HIBISCUS Trial Due to Low COVID-19 Infection and Hospitalization Rates in the US and Reverts Resources to the Development of Bexmarilimab · Traumakine will be re-positioned for multiple indications in organ protection together with partnerships · Near term value inflections are expected from the accelerated development of Bexmarilimab Company announcement, April 05, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) / 2:00 AM (EDT) Inside information TURKU, FINLAND / BOSTON, MA – Faron